Because of its lack of effect on locoregional recurrence and breast-cancer-specific mortality63,64, the Choosing Wisely initiative65 has already declared that SLNB should no longer be routinely required for women ≥ 70 years of age with early-stage hormone receptor positive, HER2-negative cN0 invasive breast cancer. Here, ERBB2 is linked to invasive breast carcinoma.